A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Janssen
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2017 Planned End Date changed from 25 Mar 2019 to 31 Dec 2018.
- 23 May 2017 Planned primary completion date changed from 15 Mar 2019 to 22 Feb 2018.